MedTech West lunch seminar with professor Anders Wallin from the Memory Clinic
WHAT IS NEEDED TO MOVE THE ALZHEIMER FIELD FORWARD?
One of the major medical challenges is to prevent or delay the development of Alzheimer’s disease (AD) and related disorders, but still efficient treatment methods are lacking. Insufficient knowledge of subcortical small vessel disease (SSVD) in AD may explain the lack of success of AD trials. Underestimation of the impact of SSVD on cognition may explain why only few trials have been performed in SSVD. The Sahlgrenska university hospital memory clinic in Mölndal, hosts the largest ongoing longitudinal single-center study in patients seeking help for memory-related complaints. To date, 808 patients along the continuum subjective cognitive impairment to dementia and 136 healthy controls have been enrolled. We aim to clarify not only the characteristics of AD but also SSVD (1), using a multi-modal approach (MRI, CSF, cognitive examination etc.). Preliminary results point to different neurochemical and cognitive characteristics of SSVD and AD also early in the course of the disease (2). Combining markers from various modalities provides a powerful tool to more precisely identify appropriate patients for clinical trials of more homogeneous populations. Thereby, the results may promote therapeutic progress not only in SSVD but also in AD.
Very welcome to this lunch seminar with professor Anders Wallin from the Memory Clinic at Sahlgrenska University Hospital, Mölndal!
Where? Förmaket, Vita stråket 12, Sahlgrenska University Hospital
When? 7 Sep, 2016 at 11:30-12:30 (13:00 incl. lunch)
After the seminar, we offer a light lunch for registered participants. Click here to register before 13:00 pm. on 2 Sep. 2016>>
1. Wallin A, Nordlund A, Jonsson M, Lind K, Edman Å, Göthlin M, Stålhammar J, Eckerström M, Kern S, Börjesson-Hanson A, Carlsson M, Olsson E, Zetterberg H, Blennow K, Svensson J, Öhrfelt A, Bjerke M, Rolstad S, Eckerström C. The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab. 2016 Jan;36(1):114-31.
2. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Öhrfelt A, Stålhammar J, Eckerström M, Carlsson M, Olsson E, Göthlin M, Svensson J, Rolstad S, Eckerström C, Bjerke M. Alzheimer’s disease–subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab. 2016 Jan;36(1):95-113.